Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis
Therapeutics and Clinical Risk Management Aug 11, 2017
Sperl J, et al. – The authors investigated the efficacy of combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. As per findings, the combination of reduced–dose sofosbuvir (SOF) and full–dose daclatasvir (DCV), daily, proved a safe and effective treatment in this patient population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
